

**Supplemental Digital Content 2.** Trial profile through the completed double-blind (Day 1 to Week 96; gray boxes) and completed open-label (Week 96 to Week 148; black boxes) phases. Further details of eligibility and detailed disposition were published in Cahn et al 2020 [7]. AE, adverse event; DTG, dolutegravir; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. <sup>a</sup>One participant withdrew after the double-blind phase and did not enter the open-label phase.

